Cyclic Guanosine Monophosphate and Risk of Incident Heart Failure and Other Cardiovascular Events: the ARIC Study

Background Cyclic guanosine monophosphate ( cGMP ) is a second messenger regulated through natriuretic peptide and nitric oxide pathways. Stimulation of cGMP signaling is a potential therapeutic strategy for heart failure with preserved ejection fraction ( HF p EF ) and atherosclerotic cardiovascular disease ( ASCVD ). We hypothesized that plasma cGMP levels would be associated with lower risk for incident HF p EF , any HF , ASCVD , and coronary...